Cite
MLA Citation
Christina Jackson et al.. “IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM.” Neuro-oncology, vol. 21, n.d., pp. vi122–vi123. http://access.bl.uk/ark:/81055/vdc_100094879145.0x000054